Comparison · NCT03518034-b30af052
AndroGel 1.62% vs Placebo: Time From Randomization to the First Component Event of CV Safety Endpoint: Number and Percentage of Participants With an Event
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AndroGel 1.62% vs Placebo: Time From Randomization to the First Component Event of CV Safety Endpoint: Number and Percentage of Participants With an Event. Trial comparisons, record NCT03518034-b30af052. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03518034-b30af052
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.104 | 0.0925 | 0.116 | wilson | |
| Risk in group 2 | 0.101 | 0.0904 | 0.114 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00216 | -0.0144 | 0.0187 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.87 | 1.2 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.856 | 1.22 | log | |
| Number needed to treat, for one more participant with the outcome on AndroGel 1.62% than on Placebo | 463 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AndroGel 1.62% | Participants received topical testosterone starting with a 40.5 mg dose (2 pump actuations) of the study drug OD. Participants may have received a dose in the range of 20.25 mg (1 actuation) to 101.25 mg (5 actuations) in 20.25 mg increments during the course of the study if titrations were necessary. | 269 | 2,596 | OG000 |
| Group 2 | Placebo | Participants received matching placebo OD. | 264 | 2,602 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Time From Randomization to the First Component Event of CV Safety Endpoint: Number and Percentage of Participants With an Event
- Description
The CV safety endpoint is a composite endpoint including non-fatal MI, non-fatal stroke, CV death, and coronary revascularization procedures/cardiac percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG) as adjudicated by CEC.
- Time frame
- Randomization to event or last known date if no event (up to approximately 52 months).
- Population
- TRAVERSE Main Study Safety Set: all randomized participants who received at least one dose of study drug and have no duplicate/triplicate participant IDs.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
- NCT number
- NCT03518034
- Phases
- PHASE4
- Conditions
- Hypogonadism, Cardiovascular Diseases
- Interventions
- AndroGel®, Placebo
- Lead sponsor
- AbbVie
- Results first posted
- 2024-03-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03518034?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03518034-b30af052